Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496) Chosen as Headline Partner for Psychedelics Symposium

May 5, 2020 10:41:00
  • Established as an industry leader in psychedelics, chosen as headline partner for PSYCH
  • Importance of mental health has been brought to the forefront during COVID-19 pandemic
  • Changing public opinion of psychedelics for medicinal purposes with help of psychedelic events such as PSYCH

Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a research-driven company specializing in the formulation and distribution of a suite of artisanal mushroom health supplements, will be the headline partner for Prohibition Partners LIVE’s PSYCH: The Psychedelics Symposium (PSYCH) ( Slated for June 22-23, 2020, this Prohibition Partners LIVE event brings together health care, science and business leaders from around the world to discuss new findings in the cannabis and psychedelic space.

Recent legal changes in the cannabis space have opened space for changing public perception of psychedelics as well as the legal research for medicinal use. As a headline partner for this premier gathering, Champignon will be actively involved in the two-day symposium, which features five virtual stages and will include topics such as:

  • Psychedelics 101
  • Psychedelics as medicine
  • Psychedelics for substance-use disorders
  • Psychedelics: the cure for treatment-resistant depression
  • Psychedelic for well-being
  • Next steps for investors

“The impact of COVID-19 has put greater emphasis on the importance of mental health,” Prohibition Partners’ managing director Stephen Murphy stated in a news release. “Consumers are looking for options to improve their mental health and, as the body of evidence mounts for psychedelics, the healthcare industry is responding with solutions. We’re delighted to partner with Champignon Brands on PSYCH and support their vision of improving mental health via psychedelics.”

As an industry leader in innovative treatments using psychedelics for mental-health conditions, SHRM currently has three trials in phase 1, three trials in the preclinical stage and seven IP patents for ketamine/psilocybin delivery platforms and formulations. The company is quickly establishing a clinical pipeline and drug-development platform in medicinal psychedelics as well as promoting the health and wellness benefits of functional mushrooms. SHRM believes that through sustainable organic, non-GMO and vegan-growing practices combined with commercial cultivation, R&D and the distribution of its products, the company can enhance the health and wellness of millions.

According to an article in Forbes (, psychedelic events are becoming mainstream when the focus is on mental health. These substances have been misunderstood, much as cannabis was, but that is changing with the help of virtual platforms such as Prohibition Partners LIVE and opportunities to join leaders on a global stage to discuss the research-backed breakthroughs in the industry.

SHRM specializes in the formulation and distribution of a suite of medicinal mushroom health products as well as novel ketamine, anaesthetics and adaptogenic delivery platforms that promote holistic health and wellness. The company’s portfolio is focused on the health-conscious consumer and offers organic teas, coffees and other consumables. Mushroom infused teas and accessories are available to the consumer on the flagship e-commerce store,

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published:

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
303.498.7722 Office

CannabisNewsWire is part of the InvestorBrandNetwork.